Best-in-class antibody drug conjugation technology
Ambrx uses a rational, structure based approach, combined with the power of an expanded genetic code, to create optimized site-specific antibody conjugates.
By using conjugation chemistries that are orthogonal to the native twenty amino acids, we create antibody conjugates with unprecedented homogeneity with respect to the site of drug attachment. Quantitative experimentation with homogenous antibody conjugates enables an efficient, robust and science driven path for optimizing efficacy, safety and biophysical properties to meet target product profiles.
Ambrx is developing antibody drug conjugates (ADCs) for oncology as well as non-oncology indications. ADCs function via the targeted delivery of a cytotoxic payload to the tumor cell or the targeted delivery of an agonist/antagonist payload to modulate a specific biological receptor or signaling pathway.
Ambrx ADC showing site-specific conjugation:
Our collaboration partners have generated pre-clinical data sets that demonstrate Ambrx antibody conjugates have significant performance advantages over older, conventional conjugation techniques that utilize cysteine and lysine residues.
- Significantly wider therapeutic Index
- PK similar to the naked wild-type antibody
- Increased drug-linker stability in rodent and human plasma
- Biophysical properties that minimize aggregate formation
To fully leverage our antibody conjugation platform, we have created novel, potent payloads with mechanisms of action that are well established in oncology and non-oncology indications.
© Copyright 2006-2012 Ambrx Inc. All right reserved.